NCT02390635View on ClinicalTrials.gov

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions
Acute Myeloid LeukemiaAcute Promyelocytic Leukemia With PML-RARA
Interventions
PROCEDURE

Computed Tomography

Undergo 18F-FDG PET/CT

PROCEDURE

Diffusion Weighted Imaging

Undergo whole body PET/MRI

RADIATION

Fludeoxyglucose F-18

Undergo 18F-FDG PET/CT

DRUG

Gadolinium

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo whole body PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo 18F-FDG PET/CT and whole body PET/MRI

PROCEDURE

Three-Dimensional Spoiled Gradient MRI

Undergo whole body PET/MRI

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02390635 - PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter